Studies muscle loss from bed rest in older adults with diabetes
Studies how bed rest affects muscle loss and recovery in older adults with diabetes.
Key facts
- Who runs it
- AdventHealth Translational Research Institute
- Where
- Orlando, United StatesSee the site
- Trial code
- Registry title
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 18 Mar 2019
- Planned end
- Dec 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Bed rest
- Record updated
- 13 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 to 80 with pre-diabetes or type 2 diabetes. A non-diabetic control group also takes part. It studies muscle loss during bed rest and recovery afterwards.
- Age
- 60 to 80 years
- Sex
- Men and women
- Disease stage
- Pre-diabetes or type 2 diabetes with an A1C below 8.0, or a non-diabetic control group with an HgbA1c below 5.7% (39 mmol/mol)
- Earlier treatment
- People with diabetes can only take DPP-4 inhibitors, sulfonylureas and/or metformin. They cannot take insulin, injectable incretin mimetics, SGL2 inhibitors or thiazolidinediones.
- Biomarker or test result
- Kidney function (eGFR) above 45 ml/min/1.73m2; triglycerides below 350 mg/dl (4 mmol/L); LDL cholesterol 150 mg/dl (3.9 mmol/L) or lower
Main reasons for not taking part
- Type 1 diabetes
- BMI above 40.0 kg/m2
- History of blood clots (DVT or pulmonary embolism), stroke, or clotting or bleeding disorders
- Smoking or nicotine use in the last 3 months
- Active cancer or autoimmune disease
The registry criteria, word for word
Show all 41 criteriaShow less
Who can take part
- Participant must be male or female between the ages of 60 and 80 years of age
- Participant has pre-diabetes or type 2 diabetes and is only taking DPP-4 inhibitors, Sulfonylureas and/or Metformin therapy (but not Insulin, injectable incretin mimeticsSGL2 inhibitors, and Thiazolidinedione's), and has an A1C < 8.0; Pre-Diabetics are defined as having an HgbA1c of greater than or equal to 5.7% and less 6.5%, or a fasting glucose of greater than or equal to 100 mg/dl and less than 126 mg/dl or has a glucose of greater than or equal to 140 mg/dl and less than 200mg/dl at the 2 hour blood draw during OGTT; The non-diabetic control group is defined as having an HgbA1c of less than 5.7%, a fasting glucose of less than 100 mg/dl and a glucose level less than 140 mg/dl at the 2hr blood draw during the OGTT
- Participant must have renal function with an estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73m2 determined at screening
- Participant's triglyceride level is < 350 mg/dl and LDL cholesterol is ≤ 150 mg/dl at screening
- Participants must be non-smokers. Non-smokers as defined by not smoking any tobacco or using nicotine-containing products and not using vape pens or vaporizers within 3 months prior to screening
- Participant states willingness to follow protocol as described, including consumption of study product per protocol, the prescribed activity level and completing any forms needed throughout the study
- Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study
Who cannot take part
- Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit
- Participant is currently taking anti-inflammatory medication or has anti-inflammatory medication in the 1 weeks prior to screening (including over the counter formulations; e.g. Aleve, Motrin, ibuprofen, naproxen)
- Participant has had surgery requiring > 2 days of hospitalization in the last 1 month prior to screening visit
- Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained
- Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos
- Participant has type 1 Diabetes
- Participant has a history of pressure ulcers
- Participant has a stated history of Deep Vein Thrombosis (DVT), pulmonary embolism, or a known hypercoagulable condition, or other clotting or bleeding disorders
- History of gastrointestinal or intracranial hemorrhage
- History of stroke or cerebrovascular accident
- Recent history of major trauma (within 3 months)
- Untreated or poorly controlled hypertension (SBP > 150, DBP > 95), or hypotension (SBP <100 DBP <60)
- Participant has an active malignancy or autoimmune disease
- Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV
- Participant has a history of, or currently has uncontrolled severe diarrhea, nausea or vomiting
- Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery
- Participant has a sensitivity or allergy to lidocaine
- Participant has a sensitivity or allergy to heparin, enoxaparin, or other low molecular weight heparin
- History of allergy to pork products or any component of the formulation of low-molecular weight heparin for dosing
- History of heparin induced thrombocytopenia
- Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study
- Thrombocytopenia (of any cause) or hyperkalemia (K > 5.0) on screening laboratory assay. May repeat lab value per PI discretion
- Participant cannot refrain from taking medications/dietary supplements/herbals or substances that could modulate glucose metabolism (other than oral hypoglycemic medications), or are considered anabolic, or reduce weight (fat mass), or that may interact with low-molecular weight heparin or induce hypo- or hyper-coagulable state, in the opinion of the PI or medical provider, starting one week prior to enrollment and over the entire course of the study. These include progestational agents (except prescribed birth control), steroids, growth hormone, dronabinol, marijuana, calcium-beta-hydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and dietary supplements to aid weight loss
- Hemoglobin < 10.0 g/dL for females; < 11.0 g/dL for males; or participant has clinically significant signs/symptoms of anemia in the opinion of the PI or medical provider
- Concomitant medications with known contraindication or interaction with low-molecular weight heparin (including anti-platelet agents, anti-coagulant agents, non-steroidal anti-inflammatory drugs)
- BMI > 40.0 kg/m2
- Participant is actively pursuing weight loss and/or lifestyle changes
- Participant has a TSH greater than or equal to 10mIU/L
- Participant has current significantly impaired liver function in the opinion of the study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit
- Participant is an amputee and/or has presence of partial or full artificial limb
- Participant cannot abstain from alcohol for the pre bed rest and bed rest portion of the study. For the recovery portion of the study the participant must agree to consume no more than 1 glass of wine (4-5 oz) or bottle of beer (12 oz) /day
- Participant has a mini-Mental State Examination score < 21
- Unable to participate in MR or DEXA assessments due to physical limitations of equipment tolerances (e.g., MRI bore size and DEXA 450-pound weight limit) claustrophobia, or based on Investigator's judgment at screening
- Participant experiences symptoms of claudication. Symptoms include cramping pain in the legs and/or difficulty walking
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 80 years old?
Where in United States
- Translational Research Institute for Metabolism and DiabetesOrlando, United StatesContact: Recruitment DepartmentTaking people
About the trial
What the trial wants to find out
The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.
The 2 groups in the trial
- Older adults with pre-diabetes or type 2 DiabetesTreatment being tested
Male and female older adults between the ages 60-80 with pre-diabetes or type 2 diabetes
Treatment: Bed rest
- Older adults without pre-diabetes or Type 2 DiabetesTreatment being tested
Male and female older adults between the ages 60-80 without pre-diabetes or type 2 diabetes
Treatment: Bed rest
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
- Plain-language title
- Studies muscle loss from bed rest in older adults with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03761446, who can take part
- Record updated
- 13 March 2025